LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Aandelen Lijst・Ardelyx Inc

Ardelyx Inc

Gesloten

SectorGezondheidszorg

6.6 -2.22

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

6.57

Max

6.82

Belangrijke statistieken
By Trading Economics
Inkomsten	-37M -38M
Verkoop	-31M 94M
EPS	-0.15
Winstmarge	-39.805
Werknemers	489
EBITDA	-42M -32M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+144.84% upside

Dividenden
By Dow Jones
Volgende Winsten	3 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	334M 1.8B
Vorige openingsprijs	8.82
Vorige sluitingsprijs	6.6

Nieuwssentiment

By Acuity

26%

74%

60 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

3.62 / 3.95 Steun & Weerstand

Ardelyx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 mei 2026, 23:47 UTC

Marktinformatie

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 mei 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 mei 2026, 23:38 UTC

Marktinformatie

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 mei 2026, 23:14 UTC

Marktinformatie

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 mei 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 mei 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 mei 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 mei 2026, 10:21 UTC

Winsten

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 mei 2026, 06:05 UTC

Winsten

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 mei 2026, 23:55 UTC

Winsten

Review & Preview: Still Going Strong -- Barrons.com

8 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 mei 2026, 20:49 UTC

Winsten

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mei 2026, 20:25 UTC

Winsten

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mei 2026, 19:43 UTC

Winsten

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mei 2026, 19:43 UTC

Winsten

Cencosud 1Q Net $115M

8 mei 2026, 19:20 UTC

Marktinformatie

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mei 2026, 19:18 UTC

Winsten

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mei 2026, 19:16 UTC

Winsten

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mei 2026, 19:08 UTC

Winsten

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mei 2026, 19:05 UTC

Winsten

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mei 2026, 19:02 UTC

Marktinformatie

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mei 2026, 18:51 UTC

Winsten

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mei 2026, 18:49 UTC

Winsten

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mei 2026, 18:41 UTC

Winsten

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mei 2026, 17:38 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mei 2026, 17:14 UTC

Winsten

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mei 2026, 17:04 UTC

Marktinformatie

Zcash Caps Off Parabolic Week -- Market Talk

8 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Ardelyx Inc Prognose

Koersdoel

By TipRanks

144.84% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.6 USD 144.84%

Hoogste 19 USD

Laagste 13 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ardelyx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Ardelyx Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.62 / 3.95Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

60 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.